Drug Profile
TH 9407
Latest Information Update: 20 Mar 2008
Price :
$50
*
At a glance
- Originator Theratechnologies
- Developer Theratechnologies; University of Montreal
- Class Antivirals
- Mechanism of Action HIV replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 21 Feb 2000 No-Development-Reported for HIV infections treatment in Canada (Unknown route)
- 20 Feb 1997 Preclinical development for HIV infections treatment in Canada (Unknown route)